SCHEMBL2501589

SCHEMBL2501589

CN1c2ccc(C=C(c3ccccc3)c3ccccc3)cc2Sc2cc(C=C(c3ccccc3)c3ccccc3)ccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 7/20 0.49
L3MBTL1 Q9Y468 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
CHRM3 P20309 1/20 0.45
SLC6A2 P23975 1/20 0.45
HTR2C P28335 1/20 0.45
SLC6A4 P31645 1/20 0.45
DRD3 P35462 1/20 0.45
HTR2B P41595 1/20 0.45
MAOA P21397 1/20 0.44
PTGS2 P35354 2/20 0.42
MAPK1 P28482 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
CYP19A1 P11511 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2498026 0.87 NOX1 (0.48) NOX1L3MBTL1MEN1KMT2AADRA2A
SCHEMBL2498028 0.87 NOX1 (0.48) NOX1L3MBTL1MEN1KMT2AADRA2A
SCHEMBL8183837 0.84 PTGS2 (0.39) NOX1L3MBTL1MEN1KMT2APTGS2
SCHEMBL2495862 0.84 CYP19A1 (0.39) NOX1L3MBTL1MEN1KMT2APTGS2
SCHEMBL8192034 0.81 PTGS2 (0.44) NOX1L3MBTL1MEN1KMT2APTGS2
SCHEMBL8711143 0.78 MAOA (0.56) NOX1L3MBTL1MEN1KMT2AADRA2A
SCHEMBL5486677 0.77 TDP1 (0.42) L3MBTL1MEN1KMT2APTGS2MAPK1
SCHEMBL2497089 0.77 MAOA (0.45) NOX1MAOAPTGS2CYP19A1CYP11B2
SCHEMBL12723325 0.75 PTGS2 (0.39) MEN1KMT2APTGS2MAPK1TDP1
SCHEMBL1418367 0.72 MAOA (0.61) NOX1L3MBTL1MEN1KMT2AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817806-B1 PHENOTHAZINES-S-OXIDES AND S,S-DIOXIDES AS hole and excitonblockers for OLEDs BASF SE (DE) 2014-07-30 EP disclosed
US-8029919-B2 Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs BASF AKTIENGESELLSCHAFT (DE) 2011-10-04 US disclosed
US-8029919-B2 Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs BASF AKTIENGESELLSCHAFT (DE) 2011-10-04 US disclosed
US-8029919-B2 Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs BASF AKTIENGESELLSCHAFT (DE) 2011-10-04 US disclosed
US-20100308714-A1 Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds BASF AKTIENGESELLSCHAFT (DE) 2010-12-09 US disclosed
US-20100308714-A1 Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds BASF AKTIENGESELLSCHAFT (DE) 2010-12-09 US disclosed
US-20100308714-A1 Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds BASF AKTIENGESELLSCHAFT (DE) 2010-12-09 US disclosed
EP-1817806-A1 PHENOTHAZINES, -S-OXIDES, AND S,S-DIOXIDES AS WELL AS PHENOXAZINES AS EMITTERS FOR OLEDS BASF AKTIENGESELLSCHAFT (DE) 2007-08-15 EP disclosed
WO-2006056465-A1 PHENOTHIAZINES, -S-OXIDES, AND S,S-DIOXIDES AS WELL AS PHENOXAZINES AS EMITTERS FOR OLEDS BASF AKTIENGESELLSCHAFT (DE) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100308714-A1 Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds PPOX, SMOX, SORD NOX1 458/4885L3MBTL1 2540/4885MEN1 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.